☆ 4.7 Meeting Abstract

Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

ANNALS OF ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 33, Issue 7, Pages S633-S634

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.07.250

Keywords

-

Categories

Oncology

Funding

  1. F. Hoffmann-La Roche Ltd.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.